Industry Trends

Recent study compared patient enrollment trends in industry- and federally sponsored oncology trials.

By embracing this leadership approach, clinical research stakeholders can prioritize more effective staff training and readiness.

Four strategies for implementing this approach in clinical trial staff and site training.

Industry leaders discuss the progress and path forward for the clinical trials enterprise in meeting its environmental mandate.

New research updates estimated value of lost time.

Highlighting the inherent risks associated with subtle biases in clinical research practice, as well as the most proven strategy for mitigating each risk.

Biotechs can successfully overcome bottlenecks in time-to-market for new drugs by embracing contracting innovations with the same passion applied to research breakthroughs.

Sharing an entertaining dive into the origins, milestones, and future of behavioral economics—where lessons can be applied to clinical practice.

The concept of sludge provides an invaluable lens for clinical research professionals in identifying and mitigating unnecessary friction and bottlenecks.

Following a webinar on what the clinical trials space will look like for the remainder of 2024, ACT caught up with Getz and Murphy to discuss their biggest takeaways.

A study conducted by the Tufts CSDD in collaboration with CluePoints and PwC revealed that slightly more than half of sponsors and contract research organizations have adopted risk-based quality management approaches.

Systematic review of over 800 retracted articles suggest that better identification of postretraction citations should be implemented.

In part 1 of this video interview, Greg Sturmer, co-founder and CEO of Elysium Therapeutics discusses the current state of opioid usage including how pain treatment is often mismanaged and how the industry can adopt greater safety standards in developing pain therapies.

Systematic review of 127 recent platform trials showed insufficient reporting of important trial information.

Cross-sectional study of recent FDA drug approvals evaluated how closely they were aligned with US and global burden of disease.

Leveraging an essential, new set of behaviorally informed best practices to break free from the constraints of the Iron Triangle of Clinical Trial Complexity.

A recent study showed that a multimodal machine learning approach accelerated the time in which investigators could determine the efficacy of sertraline treatment in major depressive disorder

Adjusting to the changing dynamics of the clinical research associate role.

The DCT-driven evolution requires new levels of understanding and expertise.

Embracing behavioral changes can lead clinical operations professionals toward driving meaningful outcomes.

Ensuring equitable access to new technologies and integrating AI to benefit all communities remain critical challenges to overcome.

Howell shares important insights from the most recent J.P. Morgan Healthcare Conference and addresses where the clinical trials industry currently is with innovation.

A deep dive into the complex playing field for M&A and partnering pursuits in today’s increasingly make-or-break landscape for biopharma innovation.

Mirati’s oncology portfolio includes promising early phase clinical assets such as a potential first-in-class MTA-cooperative PRMT5 inhibitor and a leading KRAS and KRAS enabling program with a pair of candidates in Phase I development.

In clinical trials, Cimerli met FDA standards for biosimilarity to the reference Lucentis, including safety, efficacy, and quality.

With variation in costs between different stakeholders in clinical trials, there is often disagreement on fair market value.

In an interview with ACT editor, Andy Studna, Lieberman, Executive Director, Conferences (CHI) & Co-Founder, VP, Community and Business Development (ClinEco) discusses what ClinEco is and how the need to create it came about.

Study examines how many registered clinical trials with published protocols are also publishing their results.

Utilizing known processes and managing risks are among best practices with new technologies, such as artificial intelligence, according to Gottlieb.

DCTs, data, and analytics are all areas that could be impacted in the near future.